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The term uveitis is used clinically to describe a heteroge-
neous group of diseases, characterized by inflammation of
intraocular structures.
Although frequently associated with systemic inflamma-
tory or autoimmune diseases such as Behcet' disease, JIA,
JAS, Sarcoidosis, a significant number are labeled "idio-
pathic".
TNF-alpha blockers which are an effective treatment for
systemic diseases associated with uveitis, were found
effective in uveitis in animal studies and later in clinical
trials.
Three types of TNF-alpha blockers are currently being
used: Etanercept, Infliximab and Adalimumab. For Adali-
mumab no sufficient data exist regarding the use in pedi-
atric age however recent studies show clear preference for
Infiliximab over Etanercept for childhood uveitis.
We present four children (age 4, 4.5, 6, 12) diagnosed
with chronic childhood uveitis at a very young age which
were successfully treated with Infliximab in the pediatric
rheumatology clinic at our institution. All of them were
initially treated conventionally, and switched to Anti-TNF
α because of ineffectiveness of conventional treatment or
severe side effects.
Regardless of the small cohort we found Infliximab effi-
cient and safe to use in chronic childhood uveitis at a
young age.
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